Current Status of Targeted Therapy for Advanced Renal Cell Carcinoma
Open Access
- 1 January 2012
- journal article
- Published by XMLink in Korean Journal of Urology
- Vol. 53 (4) , 217-228
Abstract
Cho IC, et al. Korean J Urol. 2012 Apr;53(4):217-228. http://dx.doi.org/10.4111/kju.2012.53.4.217Keywords
This publication has 87 references indexed in Scilit:
- Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trialThe Lancet, 2011
- Treatment of everolimus-resistant metastatic renal cell carcinoma with VEGF-targeted therapiesBritish Journal of Cancer, 2011
- Update on targeted therapies for clear cell renal cell carcinomaCurrent Opinion in Oncology, 2011
- Challenges and opportunities for converting renal cell carcinoma into a chronic disease with targeted therapiesBritish Journal of Cancer, 2011
- Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III TrialJournal of Clinical Oncology, 2010
- Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell CarcinomaJournal of Clinical Oncology, 2009
- Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation TrialJournal of Clinical Oncology, 2009
- Sequential Sorafenib and Sunitinib for Renal Cell CarcinomaJournal of Urology, 2009
- Sunitinib for Treatment of Advanced Renal Cell Cancer: Primary Tumor ResponseClinical Cancer Research, 2008
- Sorafenib in Advanced Clear-Cell Renal-Cell CarcinomaNew England Journal of Medicine, 2007